Research Updates
Tirzepatide 15 mg: 1.60 kg of Fat-Free Mass Lost
Tirzepatide 15 mg cut fat-free mass by 1.60 kg in a meta-analysis of 19 trials, where laboratory screening found risk the trial reports missed.
Tirzepatide in Prader-Willi: 3 Measures After One Swap
Tirzepatide replaced a GLP-1 agonist in a woman with Prader-Willi syndrome and refractory diabetes, and appetite, weight and glucose all improved.
GLP-1 in Resistant Hypertension: Equal BP, 4,153 Pairs
GLP-1 agonists and mineralocorticoid antagonists cut blood pressure almost equally in 4,153 matched pairs, yet the hard outcomes separated sharply.
Tirzepatide and Metformin: When Glucose Masks Ketoacidosis
Tirzepatide with metformin preceded severe lactic acidosis and ketoacidosis at near-normal glucose in a 59-year-old woman, who recovered on dialysis.
Semaglutide vs Pair-Fed Rats: Splitting Drug From Weight
Semaglutide and pair-fed rats both gained on reproductive measures, but the hormone results separated the drug effect from the weight loss effect.
Semaglutide Extended Lifespan in Mice Treated at 20 Months
Semaglutide started at 20 months extended lifespan in female mice and beat matched calorie restriction on memory, exploration and glucose control.
Retatrutide Bought Online: A Type 1 Diabetes Case Report
Retatrutide bought online preceded ketonaemia of 4.3 mmol/L in a man with type 1 diabetes. Stool grew Shigella, and causation stays unresolved.
Semaglutide: 24 Outcomes, 63,215 Adults, One Split
Semaglutide was linked to lower neuropsychiatric event rates in 63,215 adults, and the authors report the association ran independent of weight loss.
GLP-1 and Reflux: The Same Signal in 3 Countries
GLP-1 receptor agonists drew a reflux signal in US, Japanese and Canadian databases, with reporting odds ratios running from 2.83 to 4.76.
Retatrutide at 22.1%: What the Table Does Not Show
Retatrutide reached 22.1% placebo-subtracted weight loss in an Annals review of 38 trials, where heterogeneity blocked quantitative synthesis.